A hidden “jack-in-the-box” mechanism inside T cells may hold the key to unlocking more powerful cancer immunotherapies.

One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in ...

Ryan Notti (left) and Thomas Walz (right) discovered new characteristics of a T cell receptor that are essential to a variety ...

ROTTERDAM, the Netherlands, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Pan Cancer T B.V., a biotech company pioneering next-generation ...

Under the TCR-antigen data licensing agreement, Adaptive will receive an upfront payment and additional future potential annual licensing fees under this non-exclusive, multi-year data access ...

STEM-engineered CAR T cells performed as well as or better against cancer cells than did FDA-approved CAR T cells and kept their cancer-fighting abilities for longer.

Automated TCR-T production streamlines personalized immunotherapy, reducing patient burden and improving engineered T cell quality.

On track to file a Clinical Trial Application (CTA) by year end 2025, with initial clinical data expected mid-2026Important ...

Researchers have developed a new strategy that allows engineered T cells to recognize and respond to a single tumour antigen ...

IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across ...